CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025
• Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.
• AstraZeneca's portfolio saw substantial growth with expanded approvals for Imfinzi, Tagrisso, and Lynparza, strengthening partnerships with contract manufacturers including Lonza, Dottikon, and Samsung Biologics.
• Contract manufacturers supporting treatments for autoimmune conditions showed strong performance, with Argenx's Vyvgart Hytrulo receiving expanded indications for myasthenia gravis and CIDP.
Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape
• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
• Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma.
• The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
Neogap Therapeutics Initiates Clinical Trial of Personalized Cancer Immunotherapy
• Neogap Therapeutics has commenced a Phase I/II clinical trial for its personalized Tumor Trained Lymphocyte (pTTL) therapy in Sweden.
• The pTTL therapy enhances a patient's own T cells to target neoantigens specific to their tumor, identified using the PIOR software.
• The trial is recruiting patients with stage IV metastatic colorectal cancer, with the aim of enrolling up to 16 participants across three sites.
• This approach could offer a new treatment avenue for patients with limited options, by retraining T cells without genetic modification.
© Copyright 2025. All Rights Reserved by MedPath